Bioflavonoids: selective substrates and inhibitors for cytochrome P450CYP1A and CYP1B1

被引:249
作者
Doostdar, H
Burke, MD
Mayer, RT
机构
[1] US Hort Res Lab, USDA ARS, Ft Pierce, FL 34945 USA
[2] De Montfort Univ, Sch Pharm & Pharmaceut Sci, Leicester LE1 9BH, Leics, England
关键词
human; cytochrome P450; flavonoids; inhibitors; substrates;
D O I
10.1016/S0300-483X(99)00215-2
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Interactions of six naturally occurring flavonoids (acacetin, diosmetin, eriodictyol, hesperetin, homoeriodictyol, and naringenin) with human cytochrome P450 (CYP1) enzymes were studied. The flavones acacetin and diosmetin were potent inhibitors of ethoxyresorufin O-dealkylase (EROD) activity of CYP1A and CYP1B1. Hydroxy and/or methoxy substitutions at the 3' and 4' positions in the flavonoid structures were the major factors involved in conveying selectivity for the different cytochrome P450 enzymes. Eriodictyol, homoeriodictyol and naringenin were very poor inhibitors of human CYP1A EROD activity (IC50 > 4 mu M). Hesperetin and homoeriodictyol selectively inhibited human CYP1A1 and CYP1B1. Only homoeriodictyol selectively inhibited human CYP1B1 (IC50 0.24 mu M). Hesperetin was O-demethylated by both human CYP1A1 and 1B1 to eriodictyol, which was then further metabolized by the same enzymes. Hesperetin was not metabolized by human CYP1A2 or CYP3A4. (C) 2000 Published by Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:31 / 38
页数:8
相关论文
共 40 条
[1]
METABOLISM OF ESTRADIOL BY HUMAN-BREAST CANCER [J].
ABULHAJJ, YJ ;
THIJSSEN, JHH ;
BLANKENSTEIN, MA .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (07) :1171-1178
[2]
Alexander DL, 1997, CANCER RES, V57, P4498
[3]
Flavanone absorption after naringin, hesperidin, and citrus administration [J].
Ameer, B ;
Weintraub, RA ;
Johnson, JV ;
Yost, RA ;
Rouseff, RL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (01) :34-40
[4]
[Anonymous], PHYTOCHEMICAL DICT H
[5]
DIFFERENCES IN ADULT AND FETAL HUMAN CYTOCHROME-P-450 FORMS RECOGNIZED BY MONOCLONAL-ANTIBODIES WITH SPECIFICITY FOR THE P450III FAMILY [J].
BARNES, TS ;
BURKE, MD ;
MELVIN, WT .
BIOCHEMICAL JOURNAL, 1989, 260 (03) :635-640
[6]
CYTOCHROME-P450 SPECIFICITIES OF ALKOXYRESORUFIN O-DEALKYLATION IN HUMAN AND RAT-LIVER [J].
BURKE, MD ;
THOMPSON, S ;
WEAVER, RJ ;
WOLF, CR ;
MAYER, RT .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (05) :923-936
[7]
EVIDENCE FOR TANGERETIN O-DEMETHYLATION BY RAT AND HUMAN LIVER-MICROSOMES [J].
CANIVENCLAVIER, MC ;
BRUNOLD, C ;
SIESS, MH ;
SUSCHETET, M .
XENOBIOTICA, 1993, 23 (03) :259-266
[8]
Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: Substrate specificity with model substrates and promutagens [J].
Crespi, CL ;
Penman, BW ;
Steimel, TD ;
Smith, T ;
Yang, CS ;
Sutter, TR .
MUTAGENESIS, 1997, 12 (02) :83-89
[9]
Inhibition of human cytochrome P450 1A2 by flavones: A molecular modeling study [J].
Dai, RK ;
Zhai, SP ;
Wei, XX ;
Pincus, MR ;
Vestal, RE ;
Friedman, FK .
JOURNAL OF PROTEIN CHEMISTRY, 1998, 17 (07) :643-650
[10]
DOOSTDAR H, 1995, PLANT CELL PHYSIOL, V36, P69